SAPIEN 3 Ultra RESILIA Valve for Aortic Valve Stenosis
What You Need to Know Before You Apply
What is the purpose of this trial?
The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile design) that should translate into a favorable impact on valve durability at mid- to long- term follow-up
Who Is on the Research Team?
Emilie Pelletier beaumont, MSc
Principal Investigator
Fondation IUCPQ
Josep Rodés-Cabau, MD
Principal Investigator
IUCPQ-UL
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo TAVR with the SAPIEN 3 Ultra RESILIA valve
Initial Follow-up
Clinical and echocardiographic follow-up to assess primary outcomes
Long-term Follow-up
Participants are monitored for valve performance and clinical events
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.